Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBI-1301 in NY-ESO-1 Positive Synovial Sarcoma
NCT07174427Phase 3Recruiting
- Sponsor
- Takara Bio Inc.
- Start
- Jan 2026
- Primary completion
- Mar 2032
- Countries
- 1
01
Overview
A Phase 3 trial of anti-NY-ESO-1 TCR-T in synovial sarcoma (SS), sponsored by Takara Bio Inc.. Started Jan 2026; status: recruiting.
02
Drugs
anti-NY-ESO-1 TCR-T
03
Conditions
synovial sarcoma (SS)
Beyond the preview
Go deeper on NCT07174427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07174427.